Antithrombotic and antihypertensive management 3 months after ischemic stroke: A prospective study in an inner city population

Stroke

Volumn 31, Issue 2, 2000, Pages 469-475

  Hillen, Thomas ^a   Dundas, Ruth ^a   Lawrence, Enas ^a   Stewart, Judith A ^a   Rudd, Anthony G ^c   Wolfe, Charles D A ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Antithrombotic therapy; Epidemiology; Hypertension; Prevention; Stroke management

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; GLASGOW COMA SCALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; URBAN POPULATION;

EID: 0033979671     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.2.469     Document Type: Article

References (39)

1. Diener HC. Antiplatelet drugs in secondary prevention of stroke: lessons from recent trials. Neurology. 1997;49:75-81.
2. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care: North of England Aspirin Guideline Development Group. BMJ. 1998;316: 1303-1309.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
4. European Atrial Fibrillation Trial Study Group (EAFT). Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
5. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Kerlikowske K, Perry M, Prineas R, Schron E. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke. 1997;28:2557-2562.
6. PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J (Engl). 1995;108:710-717.
7. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342: 1317-1322.
8. James PA, Cowan TM, Graham RP, Majeroni BA. Family physicians' attitudes about and use of clinical practice guidelines. J Fam Pract. 1997;45:341-347.
9. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Jencks SF. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124:292-298.
10. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28:2382-2389.
11. Coppola WG, Whincup PH, Walker M, Ebrahim S. Identification and management of stroke risk in older people: a national survey of current practice in primary care. J Hum Hypertens. 1997;11:185-191.
12. Fahey T, Lancaster T. The detection and management of hypertension in the elderly of Northamptonshire. J Public Health Med. 1995;17:57-62.
13. Bum J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1994;25:333-337.
14. O'Connell JE, Gray CS. Atrial fibrillation and stroke prevention in the community. Age Ageing. 1996;25:307-309.
15. Gariballa SE, Robinson TG, Parker SG, Castleden CM. A prospective study of primary and secondary risk factor management in stroke patients. J R Coll Physicians Lond. 1995;29:485-487.
16. van der Meulen JH, Limburg M, van Straten A, Habbema JD. Computed tomographic brain scans and antiplatelet therapy after stroke: a study of the quality of care in Dutch hospitals. Stroke. 1996;27:633-638.
17. Department of Health. Our Healthier Nation: a Contract for Health. London, UK: Her Majesty's Stationers Office; 1997.
18. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: prospective study with stroke register. BMJ. 1999;318:967-971.
19. WHO Task Force on Stroke and Other Cerebrovascular Disorders. Stroke-1989: recommendations on stroke prevention, diagnosis, and therapy: report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke. 1989;20:1407-1431.
20. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86, 1: methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry. 1988; 51:1373-1380.
21. Teasdale G, Murray G, Parker L, Jennett B. Adding up the Glasgow Coma Score. Acta Neurochir Suppl (Wien). 1979;28:13-16.
22. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
23. Lambeth Southwark, and Lewisham Health Commission. Annual report of the Director of Public Health 1995-1996. London, UK: 1996.
24. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health. 1988;78:676-679.
25. Aboderin I, Venables G. Stroke management in Europe: Pan European Consensus Meeting on Stroke Management. J Intern Med. 1996;240:173-180.
26. Kalra L, Perez I, Melbourn A. Stroke risk management: changes in mainstream practice. Stroke. 1998;29:53-57.
27. Du X, Cruickshank K, McNamee R, Saraee M, Sourbuos J, Summers A, Roberts N, Walton E, Holmes S. Case-control study of stroke and the quality of hypertension control in north west England. BMJ. 1997;314:272-276.
28. McCallum AK, Whincup PH, Morris RW, Thomson A, Walker M, Ebrahim S. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? Br J Gen Pract. 1997;47:417-421.
29. Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ. 1991;302:91-92.
30. Bradley F, Morgan S, Smith H, Mant D. Preventive care for patients following myocardial infarction. The Wessex Research Network (WReN). Fam Pract. 1997;14:220-226.
31. Prencipe M, Culasso F, Rasura M, Anzini A, Beccia M, Cao M, Giubilei F, Fieschi C. Long-term prognosis after a minor stroke: 10-year mortality and major stroke recurrence rates in a hospital-based cohort. Stroke. 1998;29:126-132.
32. ESPS Group. European Stroke Prevention Study. Stroke. 1990;21: 1122-1130.
33. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JS, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1: 1215-1220.
34. Payne JN, Milner PC, Saul C, Bowns IR, Hannay DR, Ramsay LE. Local confidential inquiry into avoidable factors in deaths from stroke and hypertensive disease. BMJ. 1993;307:1027-1030.
35. Cappuccio FP, Cook DG, Atkinson RW, Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart. 1997;78:555-563.
36. Black HR. Blood pressure control. Am J Med. 1996;101:50-55.
37. Meyers DG, Steinle BT. Awareness of consensus preventive medicine practice guidelines among primary care physicians. Am J Prev Med. 1997;13:45-50.
38. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA. 1995;274:700-705.
39. McCartney P, Macdowall W, Thorogood M. A randomised controlled trial of feedback to general practitioners of their prophylactic aspirin prescribing. BMJ. 1997;315:35-36.